{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bronchiectasis/management/covid-19/","result":{"pageContext":{"chapter":{"id":"1e90ec28-8eea-5ab7-ac76-2df1ace279de","slug":"covid-19","fullItemName":"Scenario: COVID-19","depth":2,"htmlHeader":"<!-- begin field 7601ce5c-1ff9-4599-909a-ab9c00b4d04b --><h2>Scenario: COVID-19</h2><!-- end field 7601ce5c-1ff9-4599-909a-ab9c00b4d04b -->","summary":"Covers management when considering the possibility of COVID-19.","htmlStringContent":"<!-- begin item 439e9a3f-8070-486d-9162-ab9c00b4cfc8 --><!-- begin field 013b75f0-6196-41c4-9cd4-acd900acb7d8 --><p>From age 12 months onwards.</p><!-- end field 013b75f0-6196-41c4-9cd4-acd900acb7d8 --><!-- end item 439e9a3f-8070-486d-9162-ab9c00b4cfc8 -->","topic":{"id":"96a8622b-46f5-55fa-b729-6748e3d98c98","topicId":"26fab339-e333-44ec-a481-de87a29052f3","topicName":"Bronchiectasis","slug":"bronchiectasis","lastRevised":"Last revised in January 2021","chapters":[{"id":"43d88c30-f768-5e1c-a6ea-5596c5577fb5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac4fde9a-5fd3-5ed9-9201-f714bda470bb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0b34af83-d49a-5145-8589-e8748b8646c0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04eeb1ae-4fc3-5418-83a2-b62587d8bdda","slug":"changes","fullItemName":"Changes"},{"id":"dbd8ad5a-871c-59b8-9729-444e11ac9df1","slug":"update","fullItemName":"Update"}]},{"id":"b89644c6-805f-50b4-991d-36bb2b0fbf67","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d38de329-73b8-5fed-83ef-f836b765cd3f","slug":"goals","fullItemName":"Goals"},{"id":"3c116665-5586-5551-909c-0efc1ef0be62","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"60e13bc0-e351-5c39-b8ff-9a8d4514bf16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ee37cc0-9ff4-5bbd-ab3f-0a30cb904bb5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d155aa4f-7dfe-575d-a7dd-a87774f4cbad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"07c3e24b-c950-516e-9070-5441a07b3791","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5146c866-f0a7-54a6-a5ac-8aff4b385cc6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e2107a7e-b7c3-5ba9-94e4-6217ea79a3f2","slug":"definition","fullItemName":"Definition"},{"id":"39df7c47-de08-57ae-aa40-89a7d4d7b031","slug":"causes","fullItemName":"Causes"},{"id":"ac4d346e-97d4-5d84-a704-fbdcf56be7f4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e07a8b0b-866c-5789-85ef-020a5b19b620","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"ef5c5e7b-3cf4-5939-85e0-b61cae41f945","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ce267b5b-70dd-52bd-ad83-6123bd42fa0d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c605c0b9-0519-50e1-abd8-2dc47de7278a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"23a1627d-30f7-5ba4-95f8-060faf797f51","slug":"suspected-infective-exacerbation-diagnosis","fullItemName":"Suspected infective exacerbation diagnosis"}]},{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","fullItemName":"Management","slug":"management","subChapters":[{"id":"0180d43c-dd8d-5a87-915c-629542f782fe","slug":"suspected-bronchiectasis","fullItemName":"Scenario: Suspected bronchiectasis"},{"id":"290c51ae-6521-5c03-b12e-117e40c88883","slug":"infective-exacerbation","fullItemName":"Scenario: Infective exacerbation"},{"id":"1e90ec28-8eea-5ab7-ac76-2df1ace279de","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6db0266e-4d15-5eec-b2c0-ed20f472eeb5","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"a98b5813-5589-5247-9c65-e9ae534d88c2","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"04c99c8f-7a1d-55f0-85a2-6d0e1bc3e4e3","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"26b521e3-9c5e-5a7c-956b-7f3f39f2e58c","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"6cd6079a-be84-5279-9d10-e3bf4653c049","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"8ed4a900-3e69-51c0-8cd5-c2b0bee9bfe2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"5217d027-064d-5543-93b0-7e8bb1a1c0fc","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cf1fbf18-e60a-54f7-bbc4-2a30ab37f565","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8e888abe-cb05-5343-b6e3-547dea7312cc","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"}]},{"id":"118b4e08-e6ae-510a-b2f5-51b109ef3395","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecf8de37-d8f0-5ced-af38-9be20fa73de9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1c227675-02ea-5c9e-a927-e385987adf53","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f74bbe64-1998-528f-b811-df2a14219de7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a925d45-6865-5cd5-9624-23da53ee221a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a6ff3076-9be6-55b4-b373-f40cb3045f2c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67608f46-5eba-58f9-86e3-0e0e3f57d921","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3fae7f8d-20fb-5fe6-af57-64882afceb3a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"e9c86512-e5af-50c4-ba93-f8a412e186ba","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 9ad99a0a-3524-46a2-8050-ab9c00b4d055 --><h3>How should my management vary when considering the possibility of COVID-19?</h3><!-- end field 9ad99a0a-3524-46a2-8050-ab9c00b4d055 -->","summary":null,"htmlStringContent":"<!-- begin item af5fd7b1-c7e1-4065-a170-ab9c00b4d054 --><!-- begin field 29e72fd7-74d6-49b2-b491-ab9c00b4d055 --><h5>Management overview – specifically for people with cystic fibrosis</h5><ul><li>Advise people with cystic fibrosis, their families, and carers to continue with all their usual self-care arrangements including, for example:<ul><li>Airway clearance techniques.</li><li>Prophylactic medication, including oral and inhaled antibiotics, and muco-active agents.</li><li>Cystic fibrosis transmembrane conductance regulator (CFTR) therapies.</li><li>Diet, vitamins, and pancreatic enzyme replacement therapy.</li><li>Home exercise (following UK government guidance on shielding and protecting people defined on medical grounds as extremely vulnerable from COVID-19).</li></ul></li><li>Advise people with cystic fibrosis, their families, and carers to wash their hands and clean equipment such as face masks and mouthpieces used for nebulized therapies, or face masks used for non-invasive ventilation, by regularly using washing-up liquid or following the manufacturer's cleaning instructions.</li><li>Prescribe usual quantities of medicines to meet the patient's clinical needs, normally 30 days' supply.</li><li>Advise people with cystic fibrosis, their families, and carers to follow the advice they have previously been given about what to do if they have an exacerbation, including taking rescue medication and contacting their cystic fibrosis team.</li><li>Where possible put in place arrangements to monitor patients with cystic fibrosis closely.</li></ul><!-- end field 29e72fd7-74d6-49b2-b491-ab9c00b4d055 --><!-- end item af5fd7b1-c7e1-4065-a170-ab9c00b4d054 -->","subChapters":[{"id":"b69b3206-33f6-5daa-8173-ff777349087a","slug":"basis-for-recommendation-0d1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fab6139d-4135-4149-8599-ab9c00b4d057 --><h4>Basis for recommendation</h4><!-- end field fab6139d-4135-4149-8599-ab9c00b4d057 -->","summary":null,"htmlStringContent":"<!-- begin item 0d1a7ea4-c33b-49e4-871a-ab9c00b4d057 --><!-- begin field c441e2af-c1b4-4c96-91de-ab9c00b4d057 --><p>These recommendations are based on <em>COVID-19 rapid guideline: cystic fibrosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">NICE, 2020</a>].</p><p>The recommendation to only prescribe 30 days of medication is based on pragmatic advice from the National Institute of Health and Care Excellence as prescribing larger quantities of medicines will put the supply chain of medications at risk.</p><p>The recommendation to monitor people with cystic fibrosis is because they may be at greater risk of rapid deterioration if they contract COVID‑19.</p><!-- end field c441e2af-c1b4-4c96-91de-ab9c00b4d057 --><!-- end item 0d1a7ea4-c33b-49e4-871a-ab9c00b4d057 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}